title: Therapies: Progressive steps.
authors.forename: Elie
authors.initials: E
authors.lastname: Dolgin
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology / Q000378:metabolism; D001384:Azetidines / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D001549:Benzamides; D001593:Benzyl Compounds / Q000627:therapeutic use; D001812:Blood-Brain Barrier / Q000378:metabolism; D002986:Clinical Trials as Topic; D018450:Disease Progression; D004285:Dogs; D017277:Drug Approval; D000068876:Fingolimod Hydrochloride / Q000627:therapeutic use; D065026:Hope; D006801:Humans; D008297:Male; D051379:Mice; D020528:Multiple Sclerosis, Chronic Progressive / Q000175:diagnosis / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010880:Piperidines; D057285:Precision Medicine / Q000639:trends; D011725:Pyridines / Q000627:therapeutic use; D000069283:Rituximab / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D014451:Ubiquinone / Q000031:analogs & derivatives / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D007212:Indolizines; D011720:Pyrazoles
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20; D001384:Azetidines; D001549:Benzamides; D001593:Benzyl Compounds; D000068876:Fingolimod Hydrochloride; D018696:Neuroprotective Agents; D010880:Piperidines; D011725:Pyridines; D000069283:Rituximab; D013844:Thiazoles; D014451:Ubiquinone; C533411:ocrelizumab; C036619:idebenone; C038366:ibudilast; D007212:Indolizines; D011720:Pyrazoles; C526575:masitinib; C578989:siponimod